Allievex, a clinical�stage biotechnology company founded by Pappas Capital, is developing novel therapies for the treatment of rare pediatric neurodegenerative diseases. Allievex's lead product candidate is tralesinidase alfa, an investigational enzyme replacement therapy using a novel fusion of recombinant human alpha�N�acetyglucosaminidase (NAGLU) with a peptide derived from insulin�like growth factor 2 (IGF2) for the treatment of children with Sanfilippo syndrome type B or mucopolysaccharidosis IIIB (MPS IIIB).

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
10/23/19	undisclosed	Series A	Novo Holdings Pappas Capital	undisclosed